Tuesday, July 1, 2025 7/1/2025

Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors

Award Number: U01CA263967
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors - ABSTRACT With recent enactment of the Research to Accelerate Cures and Equity (RACE) for Children Act, there is a growing impetus to identify pediatric indications for molecularly targeted drugs. Accordingly, there is a pressing need for clinically relevant preclinical studies that can help prioritize pediatric indications for clinical application of nearly the entire universe of cancer drugs currently in development. To meet this need, we established a preclinical testing program that has created >300 genomically-characterized pediatric solid tumor patient- derived xenograft (PDX) models between the pediatric oncology programs at Memorial Sloan Kettering Cancer Center and University of California San Francisco. We propose to leverage this large portfolio of models across a diversity of diseases, along with the deep expertise of the team, to establish a NCI Pediatric In Vivo Testing Program (Ped-In Vivo-TP) Research Team focused on pediatric bone and soft tissue sarcomas, renal tumors, desmoplastic small round cell tumor (DSRCT) and other rare pediatric solid tumors. The Aims of this Research Team are: Aim 1. Integrate with the Coordinating Center and other Research Teams to prioritize agents for preclinical evaluation. We will leverage our team's translational expertise as well as existing connections to disease committees within cooperative groups to inform and facilitate new agent selection and preclinical evaluation in appropriate models to prioritize agents to advance into pediatric oncology clinical trials. Aim 2. Utilize PDX portfolios representative of disease heterogeneity to assess therapeutic agents. We will utilize the >300 PDX models from MSKCC and UCSF, supplemented with models from the PROXC consortium where necessary, to assess 8-10 therapeutic agents/year using study designs matched to the therapeutic question. All preclinical drug testing will be conducted at MSKCC. Aim 3. Align central and local data analyses to ensure rigor in results reporting. For the purposes of prioritization, we will maintain equipoise in validating (“go”) or invalidating (“no go”) therapeutic hypotheses, and will complement central data analyses with advanced local biostatistical expertise. Aim 4. Translational biomarker discovery. We will leverage the combined expertise of our Research Team to identify clinically translatable biomarkers predictive of enhanced response or drug resistance. In some cases, predictive biomarkers may not be genetic, but instead will depend on transcriptional or protein-based assays of target activity. In other cases, genomically identified biomarkers have to be translated to clinically utilizable assays. Together, the expertise and capabilities of this Research Team will support the rigorous evaluation of novel therapeutic hypotheses in clinically-representative models to enable prioritization and translation of the most promising emerging agents into biomarker-informed clinical trials for children with high risk solid tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $727,406 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	5	5/8/2025	NON-COMPETING CONTINUATION	$727,406
														Subtotal = $727,406

Issue Date FY: 2024 ( Subtotal = $730,032 )
2024	2024	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	4	6/6/2024	NON-COMPETING CONTINUATION	$730,032
2024	2024	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	001	4	8/29/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $730,032

Issue Date FY: 2023 ( Subtotal = $730,032 )
2023	2023	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	002	3	9/14/2023	NON-COMPETING CONTINUATION	$14,601
2023	2023	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	001	3	6/7/2023	NON-COMPETING CONTINUATION	$715,431
2023	2022	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	2	5/31/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $730,032

Issue Date FY: 2022 ( Subtotal = $715,431 )
2022	2022	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	2	7/1/2022	NON-COMPETING CONTINUATION	$715,431
														Subtotal = $715,431

Issue Date FY: 2021 ( Subtotal = $749,282 )
2021	2021	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	1	6/23/2021	NEW	$749,282
														Subtotal = $749,282

Grand Total All Awards = $3,652,183

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors

Award Number: U01CA263967

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer